Ranbaxy, Wockhardt flag off US generic market foray - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • Sep 7, 2000 - Ranbaxy, Wockhardt flag off US generic market foray

Ranbaxy, Wockhardt flag off US generic market foray

Sep 7, 2000

The test for the Indian pharmaceutical companies in the generic markets is well and truly underway with Ranbaxy and Wockhardt launching their cardiovascular generic, enalapril maleate tablets a week back. This was subsequent to the expiry of the patent held by the US drug major, Merck. (The US sales of Merck's brand, Vasotec, in 1999 was US$ 806 Million, i.e. approximately Rs 36.82 bn). Even earlier while Ranbaxy and Wockhardt have launched ranitidine tablets, the fact was that these were mere test cases where the companies concerned were checking out their marketing set ups. In this case, Ranbaxy has doubled its production of enalapril tablets after the launch, which it claims was successful.

As far as marketing is concerned while Wockhardt, is marketing its product through Sidmak Laboratories, its US partner, Ranbaxy has used its own US subsidiary for marketing.

However, the prices of this drug are expected to drop almost 80%90% since the US FDA has approved ANDA's of 8 other companies.

Moreover, in anticipation of enalapril patent and exclusivity expiry, Merck has been promoting Lisinopril at the expense of enalapril. Ranbaxy has already filed its ANDA for Lisinopril whose patent expires in June 2002. (Lisinopril sales in 1999 were US$ 1215 million.)

How profitable the launch turns out for Ranbaxy will only be known when the company announces its third quarter results next month. We spoke to Wockhardt and the company has said that in a full year of production it would earn around US $ 23 mn.


Equitymaster requests your view! Post a comment on "Ranbaxy, Wockhardt flag off US generic market foray". Click here!

  

More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

RANBAXY LAB SHARE PRICE


Apr 1, 2015 (Close)

TRACK RANBAXY LAB

  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MARKET STATS